Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other financing activities (2021 - 2024)

Vivos Therapeutics (VVOS) has disclosed Other financing activities for 3 consecutive years, with $500000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Other financing activities rose 15.74% to $500000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $1.1 million, a 17.67% decrease, with the full-year FY2024 number at $1.4 million, up 26.37% from a year prior.
  • Other financing activities was $500000.0 for Q4 2024 at Vivos Therapeutics, down from $509000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $645000.0 in Q1 2023 to a low of $4000.0 in Q3 2021.
  • A 3-year average of $356571.4 and a median of $432000.0 in 2023 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 15.74% in 2024; the steepest drop was 52.56% in 2024.
  • Vivos Therapeutics' Other financing activities stood at $4000.0 in 2021, then skyrocketed by 10700.0% to $432000.0 in 2023, then rose by 15.74% to $500000.0 in 2024.
  • Per Business Quant, the three most recent readings for VVOS's Other financing activities are $500000.0 (Q4 2024), $509000.0 (Q3 2024), and $100000.0 (Q2 2024).